How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, sex, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B‑cell lymphoma

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about tafasitamab with lenalidomide

Marketing authorisation indication

2.1 Tafasitamab (Minjuvi, Incyte) is indicated, in combination with lenalidomide followed by tafasitamab monotherapy, for 'the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for tafasitamab.

Price

2.3 Tafasitamab costs £705 per 200-mg powder for concentrate for solution for infusion (excluding VAT; company submission). Tafasitamab costs £120,639 for 12 months of treatment in year 1 and £95,049 for year 2 onwards. The list price of lenalidomide per 21‑capsule pack varies according to capsule size: £3,426.00 (2.5 mg), £3,570.00 (5 mg), £3,675.00 (7.5 mg), £3,780.00 (10 mg), £3,969.00 (15 mg), £4,168.50 (20 mg) and £4,368.00 (25 mg; all prices excluding VAT; BNF online accessed May 2022).

2.4 The company has a commercial arrangement, which would have applied if the technology had been recommended.